Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pirfenidone
Drug ID BADD_D01783
Description Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Indications and Usage For the treatment of idiopathic pulmonary fibrosis (IPF).
Marketing Status Prescription; Discontinued
ATC Code L04AX05
DrugBank ID DB04951
KEGG ID D01583
MeSH ID C093844
PubChem ID 40632
TTD Drug ID D02WCI
NDC Product Code 65372-1197; 46708-907; 73309-052; 46016-5310; 62207-004; 62512-0070; 69037-0013; 53104-7712; 11014-0214; 59285-013; 76072-1006; 69766-030; 50242-122; 57297-140; 46016-5312; 46438-0648; 60219-1642; 50242-121; 50242-123; 59651-199; 60219-1640; 60219-1641; 60862-005; 42571-329; 63759-7005
Synonyms pirfenidone | 5-methyl-1-phenyl-2-(1H)-pyridone | Esbriet | deupirfenidone | 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one | Deskar
Chemical Information
Molecular Formula C12H11NO
CAS Registry Number 53179-13-8
SMILES CC1=CN(C(=O)C=C1)C2=CC=CC=C2
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypophagia19.09.01.004; 14.03.01.006; 07.01.06.0100.004632%Not Available
Lichenoid keratosis23.01.01.0040.001158%Not Available
Blood count abnormal13.01.07.001--Not Available
Chronic kidney disease20.01.03.017--
Pulmonary arterial hypertension24.08.03.003; 22.06.01.0020.000906%Not Available
Treatment failure08.06.01.017--Not Available
Liver injury12.01.02.003; 09.01.07.0220.002895%Not Available
Type 2 diabetes mellitus14.06.01.003; 05.06.01.003--Not Available
Oropharyngeal pain22.02.05.022; 07.05.05.0040.008685%
Acute kidney injury20.01.03.016--
Upper-airway cough syndrome22.02.05.0300.004053%
Drug-induced liver injury12.03.01.044; 09.01.07.023--Not Available
Hepatic cancer16.07.02.004; 09.04.02.0080.000302%Not Available
Pneumocystis jirovecii pneumonia22.07.08.009; 11.03.07.0050.000453%Not Available
Faeces soft07.01.03.0080.001158%Not Available
Irregular breathing22.02.01.0260.000906%Not Available
Multiple organ dysfunction syndrome08.01.03.057--
Anal incontinence07.01.06.029; 17.05.01.0210.001158%
Liver function test increased13.03.01.0440.011001%Not Available
Abnormal loss of weight14.03.02.0190.001158%Not Available
Appendicitis perforated11.01.07.028; 07.04.06.0110.001158%
Chronic respiratory failure14.01.04.005; 22.02.06.0050.001057%Not Available
Dermatitis exfoliative generalised10.01.01.029; 23.03.07.0020.001737%Not Available
Hemiplegic migraine24.03.05.012; 17.14.02.0040.001158%Not Available
Jaw cyst16.11.03.002; 15.02.04.0350.003474%Not Available
Lung adenocarcinoma22.08.01.007; 16.19.01.0020.000604%Not Available
Lung carcinoma cell type unspecified stage IV22.08.01.019; 16.19.02.0060.000302%Not Available
Total lung capacity decreased13.19.01.0130.004632%Not Available
Terminal state08.01.03.0790.001737%Not Available
Clostridium difficile infection11.02.02.009--Not Available
The 17th Page    First    Pre   17 18    Next   Last    Total 18 Pages